Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients

International Journal of Clinical Practice

Volumn 57, Issue 4, 2003, Pages 267-272

  Jiménez García, Rodrigo ^a   Anegon M ^a   Esteban, J ^a   Carrasco, P ^a   Apaolaza, I ^b   Gil, A ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ELDERLY CARE; EXPERIMENTAL DESIGN; FEMALE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; OPEN STUDY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TIME;

AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; DELAYED-ACTION PREPARATIONS; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 0038541640     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ECEHA. Spanish study of hypertension in the elderly: first phase prevalence and characteristics of elderly hypertensive Spanish patients. Sociedad Española de Geriatría y Gerontología. Liga Española. para la Lucha contra la HTA. Sociedad Española de Cardiología. Sociedad Española de Medicina Familiar y Comunitaria. 1996 Pharma Consult Services, SA EDIPHARMA.
2. Saez Vaquero T. Cardiovascular risk profile of the elderly Spanish population: comparison between urban and rural populations. Doctoral thesis. Madrid Autonomous University, 1997.
3. Coca A. Evolution of hypertension control in Spain: results of the Controlpres 98 study. Hipertensión 1998; 15: 20-32.
4. Ménard J, Chatellier G. Limiting factors in the control of BP: why is there a gap between theory and practice? J Hum Hypertens 1995; 9: S19-S23.
5. Joint National Committee on detection, evaluation, and treatment of high blood pressure. Fifth report of the JNC-V. Arch Intern Med 1993; 53: 154-183.
6. Joint National Committee on detection, evaluation, and treatment of high blood pressure. Sixth report of the JNC-V. Arch Intern Med 1997; 57: 2413-2445.
7. WHO/ISH Guidelines Committee. 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. J Hypertens 1993; 11: 905-918.
8. British Hypertension Society. Guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630-635.
9. Feldman RD, Campbell N, Larochelle P et al. 1999 Canadian recommendations for the management of hypertension. Can Med Assoc J 1999; 161(12): S1-S17.
10. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostate hyperplasia. Drugs 1995; 49: 295-320.
11. Chung M, Vashi V, Puente J et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-687.
12. Anegon M, Esteban J, Jimenez-Garcia R et al. A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension. Clin Ther 2002; 24: 786-797.
13. Kaplan NM. The CARE study: a postmarketing evaluation of ramipril in 11,100 patients. Clinical Altace Real-world Efficacy (CARE) investigators. Clin Ther 1996; 18: 658-670.
14. Levine MA, Hamet P, Novosel S, Jolain B. A prospective comparison of four study designs used in assessing safety and effectiveness of drug therapy in hypertension management. Am J Hypertens 1997; 10: 1191-1200.
15. Khoury AF, Kaplan NM. Alpha-blocker therapy of hypertension. JAMA 1991; 266: 394-724.
16. Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270: 713-724.
17. Fernández Muñoz J, Jiménez García R, Ortega Molina P et al. Tratamiento con doxazosina en monoterapia en pacientes hipertensos con diabetes no insulino dependiente asociada. Farmacoterapia 1999; 16(1): 9-14.
18. del Barco A, Jiménez-García R, Ansede Cascuco JC et al. Tratamiento combinado con doxazosina en pacientes hipertensos no controlados con monoterapia. Hipertensión 1999; 16(5): 166-170.
19. Becerril E, Jiménez R, Astasio P et al. Efectividad de doxazosina en pacientes hipertensos con hiperplasia prostatica benigna y prostatismo asociado. Iberoam J Hypertens 1999; 4(1): 9-13.
20. De la Siera A, Coca A, Sobrino J et al. Therapeutic response may be predicted by some clinical parameters in essential hypertensive patients. J Hum Hypertens 1991; 5: 443-448.
21. Campo C. Predictores de respuesta la monoterapia antihipertensiva. Iberoam J Hypertens 1997; 3: 128-133.
22. Campo C, Segura J, Ruilope LM. Factors influencing the systolic blood pressure response to drug therapy. J Clin Hypertens 2002: 4: 35-40.
23. Nalbantgil S, Nalbantgil I, Onder R. Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. Am J Hypertens 2000; 13: 921-926.
24. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens 2000; 13: 468-474.
25. Os I, Stokke HP. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1999; 33: 791-797.
26. Os I, Stokke HP. Doxazosin GITS compared with doxazosin standard and placebo in patients with mild hypertension. Blood Press 1999; 8: 184-191.
27. Kirby RS, Andersen M, Gratzke P et al. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Br J Urol Int 2001; 87: 192-200.
28. Langdon CG. Doxazosin: a study in a cohort of patients with hypertension in general practice an interim report. Am Heart J 1991; 121: 268-273.
29. Holme I, Fauchald P, Rugstad HE et al. Preliminary results of Norwegian doxazosin postmarketing surveillance study: a 12-week experience. Am Heart J 1991; 121: 260-267.
30. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38(4): 400-409.
31. Weinberger MH, Fawzy A. Doxazosin in elderly patients with hypertension. Int J Clin Pract 2000; 54(3): 181-189.